The benefits of exercise has been proven for most rheumatic diseases, and there are lots of good reasons why #ACR25 Brian Andonian @RheumNow https://t.co/IEErXL6ynL

• https://x.com/drdavidliew/status/1982514009577570359/photo/1

New biomarkers 14-3-3η multiplex autoantibody assay improves axSpA diagnosis, especially in HLA-B27– patients. Combined with CRP & HLA-B27, detection rose to 99% (training) & 91.4% (evaluation). In HLA-B27– cases, 14-3-3η lifted detection to 70.6% & 55%. Abstract 0531 @RheumNow

#Cancers esp #hematologic & #lung are ⬆️in Pts w #inflammatory #rheum #diseases Odds ratios of hem malignancies are wide & risk stratification is imp Are we doing a good job? 🤔skin cancer screening ??- not as per general standards Abst#0172 #ACR25 @RheumNow @ACRheum https://t.co/Uve9knXD3o

• https://x.com/Janetbirdope/status/1982506974005871012/photo/1
• https://x.com/Janetbirdope/status/1982506974005871012/photo/1

Do you believe that patients w #rheumatic #diseases flare if #extreme #weather? Even 90 days after extreme weather events flares occur - loss of power, heat’ med storage = ++stressful events Is it early flare from weather & then ++stress @RheumNow @ACRrheum #ACR25 abst#0164 https://t.co/pGPwOKrKU7

• https://x.com/Janetbirdope/status/1982506545415180367/photo/1

Why do pts with #Still’s #AOSD Get hospitalized? #Sepsis 1827 unweighted & 9135 Weighted #US #hospitalizations Worse in men Black Medicaid But is it truly #infection or Still’s flare or both? Abst#0163 ACR25 @RheumNow @rheumacr #ACRBest as largest N ever! https://t.co/fLMNyQQNNj

• https://x.com/Janetbirdope/status/1982506217764450755/photo/1

Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didn’t affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m

• https://x.com/synovialjoints/status/1982499970197414083/photo/1

Phenotypes of GCA: Pt dx by PET compared to TA biopsy were: - younger -longer disease before dx -more frequent extremity claudication (still overall low) -less cranial / TA sx @RheumNow #ACR25 Abstract 0759 https://t.co/ilwa3eYmRq

• https://x.com/Dr_Brian_MD/status/1982492391803408736/photo/1

Cool study using vasculitis patient-powered reserach network (VPPRN) "SNOT-22" tool captures sinonasal symptoms; associated with disease activity (expected) but also worse among pts even in remission Very important impacter of QOL in AAV #ACR25 @RheumNow Abstr0725 https://t.co/NQBW8VnYFS

• https://x.com/EBRheum/status/1982490908848500816/photo/1
• https://x.com/EBRheum/status/1982490908848500816/photo/1

No seasonal pattern in GCA! We have also looked at this in our data and similarly found no trends It sure feels like GCA comes in waves, but data does not bear this out #ACR25 @RheumNow Abstr#0754 https://t.co/4y2elYmCRT

• https://x.com/EBRheum/status/1982487133937193089/photo/1

Accdg to this retro analysis of their prospective cohort study from Toronto, 47 pts (10%) had D2M axSpA of whom 14 had tx-refractory dse. D2M pts - longer symptom duration; ⬆️ASDAS, BASDAI, BASMI, BASFI & ⬆️CRP 💡Consider non-dse factors in D2M pts #ACR25 @RheumNow Abs0547 https://t.co/MUUyyELbw8

• https://x.com/RHEUMarampa/status/1982477322969354626/photo/1

Real-world T2T strategy from MONITOR-PsA cohort: 🎯 At 48 weeks - 33.6% (49/146) of pts achieved PASDAS 'moderate' response & 37% (54/146) achieved a 'good' response This was close to the T2T outcomes of the TICOPA trial Adapt a T2T approach in PsA tx #ACR25 @RheumNow Abs0572 https://t.co/FPiFIiO8Oe

• https://x.com/RHEUMarampa/status/1982477321555640449/photo/1
• https://x.com/RHEUMarampa/status/1982477321555640449/photo/1

RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a

• https://x.com/RichardPAConway/status/1982476060890649026/photo/1

Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective @RheumNow #ACR25 https://t.co/TJ4d56oBaJ

• https://x.com/Dr_Brian_MD/status/1982475138420650281/photo/1

SLE & arthritis: Is there a difference? Abstract #0629: - Non-deforming (ND): 73% | Jaccoud’s: 19% | Rhupus: 8% - Vs ND, Rhupus had lower odds of type I IFN signature - Time to deformities: Jaccoud's ~2 yrs vs Rhupus ~5 yrs - RNP+ predictive of Jaccoud’s @RheumNow #ACR25